M-254 is under clinical development by Johnson & Johnson and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect M-254’s likelihood of approval (LoA) and phase transition for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) took place on 28 Apr 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their M-254 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

M-254 overview

M-254 is under development for the treatment of immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy. The antibody is administered by intravenous route. It is developed based on sialic switch technology. It increases the anti-inflammatory activity of antibody-based drugs by enhancing signaling via a inflammatory pathway.

It was under development for the treatment of autoimmune disorders like inflammatory arthritis, pemphigus, multiple sclerosis, mucocutaneous lymph node syndrome (Kawasaki Disease) and idiopathic thrombocytopenic purpura.

Johnson & Johnson overview

Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases; consumer products in oral care, baby care, beauty, over-the-counter (OTC) medicines, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopaedic, general surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.

Quick View M-254 LOA Data

Report Segments
  • Innovator
Drug Name
  • M-254
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Central Nervous System
  • Hematological Disorders
  • Immunology
  • Musculoskeletal Disorders
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.